Immune Response News and Research

RSS

Innovative cell therapy shows highly promising results in pediatric patients with ALL

An innovative cell therapy against a highly aggressive form of acute lymphoblastic leukemia (ALL) continues to show highly promising results in children treated in a pilot study. Ninety-two percent of the 39 children receiving bioengineered T cells had no evidence of cancer at one month after treatment, with this complete response persisting in some cases for more than two years.

7 Dec 2014

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Novel treatments that harness the body's own immune cells to attack cancer cells demonstrate safe and durable responses in patients with relapsed and treatment-resistant blood cancers, according to data presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Comb-shaped polymers efficiently protect proteins in vivo

An enzyme that usually triggers strong allergic reactions now circulates in the veins of a group of mice without alerting the immune system. As INRS Énergie Matériaux Télécommunications Research Centre Professor Marc A. Gauthier explains in an article published in the journal Nature Communications, a polymer was used to camouflage the enzyme before it was injected into the rodents. This was achieved by coating the enzyme to avoid an immune response in a manner that does not compromise its activity.

6 Dec 2014

Study sheds new light on well-known mechanism required for immune response

A new study published in the scientific journal Proceedings of the National Academy of Sciences of the United States of America sheds new light on a well-known mechanism required for the immune response. Researchers at the IRCM, led by Tarik Möröy, PhD, identified a protein that controls the activity of the p53 tumour suppressor protein known as the "guardian of the genome".

6 Dec 2014

Scientists seek to improve stem cell transplant outcomes using DNA sequencing, mathematical modeling

Is the human immune system similar to the weather, a seemingly random yet dynamical system that can be modeled based on past conditions to predict future states? Scientists at VCU Massey Cancer Center's award-winning Bone Marrow Transplant (BMT) Program believe it is, and they recently published several studies that support the possibility of using next-generation DNA sequencing and mathematical modeling to not only understand the variability observed in clinical outcomes of stem cell transplantation, but also to provide a theoretical framework to make transplantation a possibility for more patients who do not have a related donor.

5 Dec 2014

Research to Prevent Blindness, IRRF partner to advance knowledge about AMD

Research to Prevent Blindness, the leading eye research foundation, is partnering with the International Retinal Research Foundation to advance knowledge about age-related macular degeneration (AMD) through novel stem cell research.

5 Dec 2014

Scientists report new approach to defeating asthma by targeting allergen

Current asthma treatments can alleviate wheezing, coughing and other symptoms felt by millions of Americans every year, but they don't get to the root cause of the condition. Now, for the first time, scientists are reporting a new approach to defeating asthma by targeting the trigger -- the allergen -- before it can spark an attack. They describe their new compound, which they tested on rats, in ACS' Journal of Medicinal Chemistry.

3 Dec 2014

SAFit-ligands provide foundation for novel treatment of stress-related psychiatric disorders

The FK506-binding protein 51 (FKBP51) is an established risk factor for stress-related psychiatric disorders such as major depression. Drug discovery for FKBP51 has been hampered by the inability to pharmacologically differentiate against the very similar functional counterplayer FKBP52.

3 Dec 2014

Abnormal activation of cell death pathways may lead to inflammatory skin diseases

Inflammatory skin diseases such as psoriasis may result from abnormal activation of cell death pathways previously believed to suppress inflammation, a surprise finding that could help to develop new ways of treating these diseases.

3 Dec 2014

InnaVirVax receives DSMB recommendation to pursue VAC-3S Phase 2 study in HIV

InnaVirVax, a biopharmaceutical company specialized in research and development on therapeutic and diagnostic solutions for diseases linked to immune dysregulation, today announces the recommendation of its independent Data Safety and Monitoring Board (DSMB) to pursue the Phase 2 study (IPROTECT1) of VAC-3S according to the planned protocol.

2 Dec 2014

HIV's ability to cause AIDS is declining, finds new research

The rapid evolution of HIV, which has allowed the virus to develop resistance to patients' natural immunity, is at the same time slowing the virus's ability to cause AIDS, according to new research funded by the Wellcome Trust.

2 Dec 2014

Ligand indazole chloride improves motor function, study shows

Multiple sclerosis (MS), an autoimmune disease of the brain and spinal cord, affects about 2.3 million people worldwide (400,000 in the United States). Affecting more women than men, it can be seen at any age, although it is most commonly diagnosed between the ages of 20 and 40.

2 Dec 2014

Scientists investigate Veto Cell technology to treat blood cancers, bone marrow transplants

Overcoming graft rejection is the main obstacle when it comes to stem cell regeneration or organ transplantation.

2 Dec 2014

Researchers use mathematical models to predict how immune cells respond to disease

Walter and Eliza Hall Institute researchers have defined for the first time how the size of the immune response is controlled, using mathematical models to predict how powerfully immune cells respond to infection and disease.

28 Nov 2014

Experimental drug works best when patients' immune cells surrounding tumors express PD-L1

A promising experimental immunotherapy drug works best in patients whose immune defenses initially rally to attack the cancer but then are stymied by a molecular brake that shuts down the response, according to a new study led by researchers at Dana-Farber Cancer Institute and the Yale University School of Medicine.

28 Nov 2014

Ebola vaccine shows promising results in human trial

An experimental vaccine against the Ebola virus has proved effective and well-tolerated in the first human trial of a candidate Ebola drug.

27 Nov 2014

Immune-suppressing protein may predict how patients respond to treatment

The presence of an immune-suppressing protein in non-cancerous immune cells may predict how patients with different types of cancer respond to treatment, a multi-center phase I study using an investigational immune therapy drug has found.

27 Nov 2014

UTSA's Bernard Arulanandam named fellow of AAAS

Bernard Arulanandam, UTSA Jane and Roland Blumberg Professor in Biology and Assistant Vice President for Research Support, has been named a fellow of the American Association for the Advancement of Science. Arulanandam was elected by his peers for the honor, recognizing his scientific and socially distinguished efforts to advance science and its applications.

26 Nov 2014

New hybrid vehicle to improve delivery of DNA vaccines is under development

Described recently in the Proceedings of the National Academy of Sciences, the technology is a biomedical advancement that could help unleash the potential of DNA vaccines, which despite two decades of research, have yet to make a significant impact in the treatment of major illnesses.

26 Nov 2014

Dry powdered measles vaccine triggers no adverse side effects in early human testing

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal Vaccine.

26 Nov 2014

Immune Response News and Research

Innovative cell therapy shows highly promising results in pediatric patients with ALL

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Comb-shaped polymers efficiently protect proteins in vivo

Study sheds new light on well-known mechanism required for immune response

Scientists seek to improve stem cell transplant outcomes using DNA sequencing, mathematical modeling

Research to Prevent Blindness, IRRF partner to advance knowledge about AMD

Scientists report new approach to defeating asthma by targeting allergen

SAFit-ligands provide foundation for novel treatment of stress-related psychiatric disorders

Abnormal activation of cell death pathways may lead to inflammatory skin diseases

InnaVirVax receives DSMB recommendation to pursue VAC-3S Phase 2 study in HIV

HIV's ability to cause AIDS is declining, finds new research

Ligand indazole chloride improves motor function, study shows

Scientists investigate Veto Cell technology to treat blood cancers, bone marrow transplants

Researchers use mathematical models to predict how immune cells respond to disease

Experimental drug works best when patients' immune cells surrounding tumors express PD-L1

Ebola vaccine shows promising results in human trial

Immune-suppressing protein may predict how patients respond to treatment

UTSA's Bernard Arulanandam named fellow of AAAS

New hybrid vehicle to improve delivery of DNA vaccines is under development

Dry powdered measles vaccine triggers no adverse side effects in early human testing

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News